Cargando…

Recent Advances in Nanoparticles-Based Platforms Targeting the PD-1/PD-L1 Pathway for Cancer Treatment

Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis showed remarkable improvements in overall response and patient survival, which changed the treatment landscape for multiple cancer types. However, the majority of patients receiving ICIs are either non-responders or eventually develop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Xin, Fang, Chao, Zhang, Kun, Su, Chunxia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414242/ https://www.ncbi.nlm.nih.gov/pubmed/36015206 http://dx.doi.org/10.3390/pharmaceutics14081581

Ejemplares similares

Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
por: Yuan, Yu, et al.
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
por: Kammerer-Jacquet, Solène-Florence, et al.
Publicado: (2019)

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
por: Tremblay-LeMay, Rosemarie, et al.
Publicado: (2018)

A snapshot of the PD-1/PD-L1 pathway
por: Ghosh, Chinmoy, et al.
Publicado: (2021)

The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
por: Qiao, Xin-wei, et al.
Publicado: (2020)

Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
por: Yang, Xingcheng, et al.
Publicado: (2022)

Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies
por: Chen, Meng, et al.
Publicado: (2022)

PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2020)

PD-1/PD-L1 pathway and angiogenesis dual recognizable nanoparticles for enhancing chemotherapy of malignant cancer
por: Sun, Zhenliang, et al.
Publicado: (2018)

Targeting PD-1/PD-L1 interactions for cancer immunotherapy
por: Zitvogel, Laurence, et al.
Publicado: (2012)

Targeting the PD-1/PD-L1 Axis in Human Vitiligo
por: Willemsen, Marcella, et al.
Publicado: (2020)

The Impact of Biologic Treatment on PD-1/PD-L1 Pathway Disturbances in Psoriasis
por: Adamczyk, Michał, et al.
Publicado: (2023)

Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
por: Cheng, Chao, et al.
Publicado: (2022)

Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis
por: Suszczyk, Dorota, et al.
Publicado: (2022)

Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
por: Liu, Bingshan, et al.
Publicado: (2017)

PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence
por: Tran, Phu N, et al.
Publicado: (2017)

In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
por: Lu, Chih-Hao, et al.
Publicado: (2022)

The PD-1/PD-L1 Inhibitory Pathway is Altered in Primary Glomerulonephritides
por: Grywalska, Ewelina, et al.
Publicado: (2017)

The importance of the PD-1/PD-L1 pathway at the maternal-fetal interface
por: Meggyes, Matyas, et al.
Publicado: (2019)

Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization
por: Guo, Yan, et al.
Publicado: (2021)

Targeting PD-1/PD-L1 in lung cancer: current perspectives
por: González-Cao, María, et al.
Publicado: (2015)

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
por: Qin, Weiting, et al.
Publicado: (2019)

Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death
por: Moon, Yujeong, et al.
Publicado: (2022)

PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas
por: Xie, Wei, et al.
Publicado: (2022)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1
por: Jiang, Mengzhen, et al.
Publicado: (2023)

Recent advances and application of PD-1 blockade in sarcoma
por: Zuo, Wenli, et al.
Publicado: (2019)

Rational development of molecularly imprinted nanoparticles for blocking PD-1/PD-L1 axis
por: Gu, Zikuan, et al.
Publicado: (2022)

Recent Findings in the Posttranslational Modifications of PD-L1
por: Li, Shu-Man, et al.
Publicado: (2020)

Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment—Current Progress, Strategy, and Future Perspective
por: Guo, Libin, et al.
Publicado: (2020)

Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors
por: Chen, Jianing, et al.
Publicado: (2022)

Case Report: Replacement of PD-1 inhibitors with PD-L1 inhibitors in the treatment of squamous non-small-cell lung carcinoma
por: Wu, Tong, et al.
Publicado: (2023)

The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy
por: Jiang, Wenxiao, et al.
Publicado: (2021)

Targeting the PD-1/PD-L1 axis for cancer treatment: a review on nanotechnology
por: Tran, Tuan Hiep, et al.
Publicado: (2022)

The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia
por: Jimbu, Laura, et al.
Publicado: (2021)

The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
por: Bardhan, Kankana, et al.
Publicado: (2016)

Immunosuppression in Gliomas via PD-1/PD-L1 Axis and Adenosine Pathway
por: Scheffel, Thamiris Becker, et al.
Publicado: (2021)

PD1/PD-L1 pathway in psoriasis and psoriatic arthritis: a review
por: Adamczyk, Michał, et al.
Publicado: (2022)

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
por: Zhang, Min, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_eb107u9g8drbal6u7hhqvkp3i5